Andere Sprachen Agios Pharmaceuticals, Inc.

Aktien

A1W2RM

US00847X1046

AGIO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
31,67 ^USD	0,00 %		+7,61 %	+42,21 %

16.02.	AGIOS PHARMACEUTICALS, INC. : erhält Kaufen-Rating von RBC Capital Markets	ZM
15.02.	Agios Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024	18.04.
Agios Publishes 2024 Environmental, Social and Governance Report	10.04.
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report	09.04.
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	06.03.
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	05.03.
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024	22.02.
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	15.02.
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	15.02.
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
Servier replonge dans le rouge en raison du dossier Mediator	07.02.
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024	02.02.
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing	09.01.
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08.01.
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08.01.
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints	03.01.
Agios Pharmaceuticals : ENERGIZE Phase 3 Topline Results	03.01.
Agios' blood disorder drug meets goals of late-stage study	03.01.
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03.01.
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Agios Pharmaceuticals, Inc.

Aktien

A1W2RM

US00847X1046

AGIO

Andere Sprachen

Filter